Co-treatment with other potent CYP3A inhibitors, such as itraconazole, is also expected to increase the systemic fluticasone propionate exposure and the risk of systemic side-effects. Oral or injected corticosteroids. If the pharmacy that's willing to deliver medicines to your home doesn't have flixonase nasal spray in stock, you can ask for one of the alternative medicines for flixonase nasal spray. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports and not known (cannot be estimated from the available data). The absence of an immediate effect should be explained to the patient, as maximum relief may not be obtained until after 3 to 4 days of treatment.Hypersensitivity to the active substance or any of the excipients listed in section 6.1.Local infections: infections of the nasal airways should be appropriately treated but do not constitute a specific contra-indication to treatment with Flixonase Aqueous Nasal Spray.The full benefit of Flixonase Aqueous Nasal Spray may not be achieved until treatment has been administered for several days.Care must be taken while transferring patients from systemic steroid treatment to Flixonase Aqueous Nasal Spray if there is any reason to suppose that their adrenal function is impaired.Although Flixonase Aqueous Nasal Spray will control seasonal allergic rhinitis in most cases, an abnormally heavy challenge of summer allergens may in certain instances necessitate appropriate additional therapy.Systemic effects of nasal corticosteroids may occur particularly at high doses prescribed for prolonged periods. If there is evidence for higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery (see Section 5.1 for data on intranasal fluticasone propionate).The full benefit of fluticasone propionate aqueous nasal spray may not be achieved until treatment has been administered for several days.Ritonavir can greatly increase the concentration of fluticasone propionate in plasma.
Intranasal administration of 2 mg fluticasone propionate twice daily for seven days to healthy human volunteers has no effect on hypothalamo-pituitary-adrenal (HPA) axis function.Inhalation or oral administration of high doses of corticosteroids over a long period may lead to suppression of HPA axis function.Administration of doses higher than those recommended over a long period of time may lead to temporary suppression of adrenal function.In these patients, treatment with fluticasone propionate should be continued at a dose sufficient to control.Pharmacotherapeutic group: Decongestants and other nasal preparations for topical use Corticosteroids. The total systemic absorption arising from both nasal and oral absorption of the swallowed dose is therefore negligible. Following intranasal dosing of fluticasone propionate, (200mcg/day) no significant change in 24h serum cortisol AUC was found compared to placebo (ratio1.01, 90%CI 0.9-1.14).In a 1-year randomised, double-blind, placebo-controlled, parallel group growth study in pre-pubescent children aged 3 to 9 years (56 patients receiving intranasal fluticasone propionate and 52 receiving placebo,) no statistically significant difference in growth velocity was observed in patients receiving intranasal fluticasone propionate (200 micrograms per day nasal spray) compared to placebo.

Present: 4.4 Special warnings and precautions for use . Metabolism: Fluticasone propionate is cleared rapidly from the systemic circulation, principally by hepatic metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4.

You should refer to the prescribing information for Flonase nasal spray for a complete list of interactions.Flonase (fluticasone nasal spray) [Package Insert].

Metabolism: Fluticasone propionate is cleared rapidly from the systemic circulation, principally by hepatic metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4. Fluticasone propionate causes little or no hypothalamic-pituitary-adrenal axis suppression following intranasal administration. This information is intended for use by health professionalsAqueous suspension of 0.05% w/w micronised fluticasone propionate. The minimum dose should be used at which effective control of symptoms is maintained.

Combinations should be avoided unless the benefit outweighs the potential increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.There is inadequate evidence of safety in human pregnancy. When Flixonase Aqueous Nasal Spray is used in breast feeding mothers the therapeutic benefits must be weighed against the potential hazards to mother and baby.Adverse events are listed below by system organ class and frequency.